OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background: Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). Methods: Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles in the double-blind (DB) phase, followed by three 12-week cycles of open-label (OL) onabotulinumtoxinA (onabotulinumtoxinA/onabotulinumtoxinA (O/O) and placebo/onabotulinumtoxinA (P/O) groups, respectively). HRQoL endpoints were assessed over 56 weeks using the Headache Impact Test (HIT-6) and the Migraine-Specific Quality of Life Questionnaire (MSQ). HIT-6 score reductions ≥2.3 and ≥5 denoted between-group minimally important difference and within-patient clinically meaningful response, respectively. Results: A total of 1236 participants (O/O, n = 607; P/O, n = 629) participated in both phases. The DB phase showed significantly reduced HIT-6 and MSQ for onabotulinumtoxinA versus placebo (all p < 0.001). The OL phase showed significantly reduced HIT-6 for O/O versus P/O at weeks 28, 36, and 48, but not 56. All three MSQ domains showed improved HRQoL relative to baseline, but only the role restrictive domain showed a significant difference between O/O and P/O at week 56. Conclusions: Benefits of onabotulinumtoxinA on HRQoL versus baseline persisted throughout the OL phase. Statistical superiority in favor of O/O was demonstrated for HIT-6 through 48 weeks and for MSQ (role restrictive) at 56 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
The International Classification of Headache Disorders: 2nd edition
Olesen, J., Goadsby, P., & Steiner, T. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00590-8 · Cited by 5,049
Olesen, J. (2004) · Cephalalgia · doi:10.1111/j.1468-2982.2003.00824.x · Cited by 2,056
A six-item short-form survey for measuring headache impact: The HIT-6™
Kosinski, M., Bayliss, M. S., Bjorner, J. B., Ware, J. E., Garber, W. H., Batenhorst, A., Cady, R., Dahlöf, C. G. H., Dowson, A., & Tepper, S. (2003) · Quality of Life Research · doi:10.1023/a:1026119331193 · Cited by 1,376 · cited 1×
“The validated HIT-6 is a self-administered tool that assesses the impact of headache using widely measured, functionally relevant domains: pain, social and role limitations, cognitive functioning, vitality, and psychological distress (12,13).”
MethodAurora, S., Dodick, D., Turkel, C., DeGryse, R., Silberstein, S., Lipton, R., Diener, H., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364676 · Cited by 1,047 · cited 4×
“Primary results from the 24-week, double-blind phase have been published separately for PREEMPT 1 (6) and PREEMPT 2 (7).”
BackgroundMethodInfluentialSelf-citationDodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H., & Brin, M. F. (2010) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01678.x · Cited by 994 · cited 2×
“Data from the two trials were subsequently pooled to examine the durability and precision of the individual study results and to explore other potentially relevant findings by virtue of the added statistical power (8,9).”
MethodSelf-citationDiener, H., Dodick, D., Aurora, S., Turkel, C., DeGryse, R., Lipton, R., Silberstein, S., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364677 · Cited by 960 · cited 4×
“Primary results from the 24-week, double-blind phase have been published separately for PREEMPT 1 (6) and PREEMPT 2 (7).”
BackgroundMethodInfluentialSelf-citationNew Appendix Criteria Open for a Broader Concept of Chronic Migraine
Olesen, J., Bousser, M.-G., Diener, H.-C., Dodick, D., First, M., Goadsby, P., Göbel, H., Lainez, M., Lance, J., Lipton, R., et al. (2006) · Cephalalgia · doi:10.1111/j.1468-2982.2006.01172.x · Cited by 909
Self-citationGlobal prevalence of chronic migraine: A systematic review
Natoli, J., Manack, A., Dean, B., Butler, Q., Turkel, C., Stovner, L., & Lipton, R. (2010) · Cephalalgia · doi:10.1111/j.1468-2982.2009.01941.x · Cited by 693 · cited 1×
“Variation in case definition contributes to the varying estimates of CM prevalence (ranging from 0 to 5%) in epidemiologic studies (27).”
BackgroundSelf-citationBlumenfeld, A., Varon, S., Wilcox, T., Buse, D., Kawata, A., Manack, A., Goadsby, P., & Lipton, R. (2011) · Cephalalgia · doi:10.1177/0333102410381145 · Cited by 627 · cited 2×
“Individuals with CM experience greater headache impact (1) and disability (2), reduced productivity at work, home, and school (3), decreased health-related quality of life (HRQoL) (1), and increased comorbid medical conditions, including obesity, vascular disease, and psychiatric disorders (1,2,4) compared with those…”
BackgroundSelf-citationSociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers
Buse, D. C., Manack, A., Serrano, D., Turkel, C., & Lipton, R. B. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.192492 · Cited by 622 · cited 1×
“Individuals with CM experience greater headache impact (1) and disability (2), reduced productivity at work, home, and school (3), decreased health-related quality of life (HRQoL) (1), and increased comorbid medical conditions, including obesity, vascular disease, and psychiatric disorders (1,2,4) compared with those…”
BackgroundSelf-citationValidation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
Yang, M., Rendas-Baum, R., Varon, S. F., & Kosinski, M. (2011) · Cephalalgia · doi:10.1177/0333102410379890 · Cited by 544
Self-citationChronic migraine in the population: Burden, diagnosis, and satisfaction with treatment
Bigal, M. E., Serrano, D., Reed, M., & Lipton, R. B. (2008) · Neurology · doi:10.1212/01.wnl.0000323925.29520.e7 · Cited by 490 · cited 2×
“Individuals with CM experience greater headache impact (1) and disability (2), reduced productivity at work, home, and school (3), decreased health-related quality of life (HRQoL) (1), and increased comorbid medical conditions, including obesity, vascular disease, and psychiatric disorders (1,2,4) compared with those…”
BackgroundSelf-citationTransformed or Evolutive Migraine
Mathew, N. T., Reuveni, U., & Perez, F. (1987) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.1987.hed2702102.x · Cited by 389 · cited 1×
“The specific diagnostic criteria and nomenclature for CM have evolved considerably since the condition was first termed ‘‘transformed migraine’’ in the 1980s (23,24).”
BackgroundAdams, A. M., Serrano, D., Buse, D. C., Reed, M. L., Marske, V., Fanning, K. M., & Lipton, R. B. (2015) · Cephalalgia · doi:10.1177/0333102414552532 · Cited by 305 · cited 3×
“Individuals with CM experience greater headache impact (1) and disability (2), reduced productivity at work, home, and school (3), decreased health-related quality of life (HRQoL) (1), and increased comorbid medical conditions, including obesity, vascular disease, and psychiatric disorders (1,2,4) compared with those…”
BackgroundResultSelf-citationValidity and Reliability of the Migraine‐Specific Quality of Life Questionnaire (MSQ Version 2.1)
Martin, B. C., Pathak, D. S., Sharfman, M. I., Adelman, J. U., Taylor, F., Kwong, W. J., & Jhingran, P. (2000) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2000.00030.x · Cited by 299 · cited 2×
“The MSQ has been shown to reliably measure HRQoL among patients with migraine in the outpatient setting (18).”
BackgroundMunakata, J., Hazard, E., Serrano, D., Klingman, D., Rupnow, M. F. T., Tierce, J., Reed, M., & Lipton, R. B. (2009) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2009.01369.x · Cited by 299 · cited 1×
“EM (1,3), and direct and indirect costs of CM are greater than four times higher than those associated with EM (5).”
BackgroundSelf-citationAurora, S. K., Winner, P., Freeman, M. C., Spierings, E. L., Heiring, J. O., DeGryse, R. E., VanDenburgh, A. M., Nolan, M. E., & Turkel, C. C. (2011) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2011.01990.x · Cited by 295 · cited 5×
“Data from the two trials were subsequently pooled to examine the durability and precision of the individual study results and to explore other potentially relevant findings by virtue of the added statistical power (8,9).”
BackgroundMethodInfluentialSelf-citationDevelopment and Validation of the Migraine‐Specific Quality of Life Questionnaire
Jhingran, P., Osterhaus, J. T., Miller, D. W., Lee, J. T., & Kirchdoerfer, L. (1998) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.1998.3804295.x · Cited by 252 · cited 1×
“The Role Restrictive (RR) domain measures the effect of migraine on daily social and work-related activities, the Role Preventive (RP) domain assesses whether migraine prohibits performing these activities, and the Emotional Functioning (EF) domain measures the emotions associated with migraine (16).”
BackgroundBuse, D., Manack, A., Serrano, D., Reed, M., Varon, S., Turkel, C., & Lipton, R. (2012) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2011.02046.x · Cited by 239 · cited 2×
“Study design and patient population PREEMPT 1 and 2 were conducted concurrently at 122 sites (106 in North America and 16 in Europe) between January 2006 and August 2008.”
ResultSelf-citationCoeytaux, R. R., Kaufman, J. S., Chao, R. A., Mann, J. D., & DeVellis, R. F. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.05.010 · Cited by 161
Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine
Rendas-Baum, R., Yang, M., Varon, S. F., Bloudek, L. M., DeGryse, R. E., & Kosinski, M. (2014) · Health and Quality of Life Outcomes · doi:10.1186/s12955-014-0117-0 · Cited by 157 · cited 1×
“The HIT-6 has been validated both in EM and CM (13,14).”
MethodSelf-citationOnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine
Lipton, R. B., Varon, S. F., Grosberg, B., McAllister, P. J., Freitag, F., Aurora, S. K., Dodick, D. W., Silberstein, S. D., Diener, H. C., DeGryse, R. E., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318232ab65 · Cited by 149 · cited 2×
“At the end of the double-blind phase (week 24), 41% of patients receiving onabotulinumtoxinA and 25% of patients receiving placebo had achieved the individual MID in HIT-6 score (10).”
BackgroundMethodSelf-citationRendas-Baum, R., Bloudek, L. M., Maglinte, G. A., & Varon, S. F. (2013) · Quality of Life Research · doi:10.1007/s11136-012-0230-7 · Cited by 120 · cited 3×
“Domain scores are calculated as the sum of their item scores, and then transformed to a 0–100 reversed scale in which higher scores indicate better HRQoL (17,18).”
BackgroundMethodSelf-citationCole, J. C., Lin, P. L., & Rupnow, M. F. T. (2007) · Quality of Life Research · doi:10.1007/s11136-007-9217-1 · Cited by 107 · cited 1×
“Among patients receiving prophylactic migraine therapy, the MSQ has shown stable and reliable psychometric properties, lending support for its use as an outcome measure in clinical trials (21), and was recently validated in the CM patient population (17).”
MethodCole, J., Lin, P., & Rupnow, M. (2009) · Cephalalgia · doi:10.1111/j.1468-2982.2009.01852.x · Cited by 94
The Impact of Topiramate on Health‐Related Quality of Life Indicators in Chronic Migraine
Dodick, D. W., Silberstein, S., Saper, J., Freitag, F. G., Cady, R. K., Rapoport, A. M., Mathew, N. T., Hulihan, J., Crivera, C., Rupnow, M. F. T., et al. (2007) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2007.00950.x · Cited by 83 · cited 1×
“2 (19), and the between-group MIDs are RR1⁄4 3.”
BackgroundThe Evolution of Chronic Migraine: Classification and Nomenclature
Manack, A., Turkel, C., & Silberstein, S. (2009) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2009.01432.x · Cited by 46 · cited 1×
“The specific diagnostic criteria and nomenclature for CM have evolved considerably since the condition was first termed ‘‘transformed migraine’’ in the 1980s (23,24).”
BackgroundOperational Diagnostic Criteria for Chronic Migraine: Expert Opinion
Silberstein, S. D., Lipton, R. B., & Dodick, D. W. (2014) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12407 · Cited by 45 · cited 1×
“Although the PREEMPT studies were conducted using criteria that differ from ICHD-2 and ICHD-3b criteria, the overlap in diagnostic criteria is very high (28).”
MethodSelf-citation
Research works printed but not linked: 1
- Bayliss MS, 2002, The HIT-6™: A user’s guide
Cited by
Tassorelli, C., Diener, H.-C., Dodick, D. W., Silberstein, S. D., Lipton, R. B., Ashina, M., Becker, W. J., Ferrari, M. D., Goadsby, P. J., Pozo-Rosich, P., et al. (2018) · Cephalalgia · doi:10.1177/0333102418758283 · Cited by 388
“For chronic migraine, there are no disease-specific instruments, but the instruments used for episodic migraine have performed well in capturing the impact of chronic migraine (71).”
Self-citationBendtsen, L., Sacco, S., Ashina, M., Mitsikostas, D. D., Ahmed, F., Pozo‐Rosich, P., & Martelletti, P. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0921-8 · Cited by 163
Botulinum toxins for the prevention of migraine in adults
Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J. A., Ives, N. J., Clarke, C. E., & Sinclair, A. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011616.pub2 · Cited by 149
Erenumab (AMG 334) in episodic migraine
Ashina, M., Dodick, D. W., Goadsby, P. J., Reuter, U., Silberstein, S. D., Zhang, F., Gage, J. R., Cheng, S., Mikol, D. D., & Lenz, R. A. (2017) · Neurology · doi:10.1212/wnl.0000000000004391 · Cited by 134
Pregabalin as a Pain Therapeutic: Beyond Calcium Channels
Alles, S. R. A., Cain, S. M., & Snutch, T. P. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00083 · Cited by 141
“Interestingly, onabotulinumtoxin A is effective as a therapy for the treatment of chronic migraine, which is characterized by a headache frequency of 15 episodes per month or more (Frampton, 2012; Lipton et al., 2016).”
Background
Metadata
- Authors
- Lipton, R. B., Rosen, N. L., Ailani, J., DeGryse, R. E., Gillard, P. J., & Varon, S. F.
- Affiliations
- Albert Einstein College of Medicine (US)
- Northwell Health (US)
- Georgetown University (US)
- Allergan plc, Irvine, CA, USA
- Corresponding author
- Lipton, Richard B
- Venue
- Cephalalgia
- Publisher
- SAGE Publications
- Published
- 2016-06-10
- Volume
- 36
- Issue
- 9
- Pages
- 899-908
- ISSN
- 0333-1024 (ISSN-L)
- 1468-2982
- PMC
- PMC4959035
- OpenAlex
- W2417058223
- Cited by
- 85
- References
- 29
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 10 · 2023: 7 · 2022: 5 · 2021: 6 · 2020: 15 · 2019: 5 · 2018: 16 · 2017: 10 · 2016: 4
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Cephalalgia (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Teva Pharmaceutical Industries
- National Institutes of Health
- Allergan
- Topics
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Health Sciences › Dentistry › Oral Surgery › Temporomandibular Joint Disorders
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Keywords
- onabotulinumtoxinA, chronic migraine, health-related quality of life, migraine-specific quality of life, HIT-6, Migraine-Specific Quality of Life Questionnaire, migraine prophylaxis, PREEMPT trial, long-term treatment outcomes
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Migraine Disorders, Neuromuscular Agents, Treatment Outcome, Botulinum Toxins, Type A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.